Reach Us +441474556909
Flavia Nelson | OMICS International
ISSN: 2376-0389

Journal of Multiple Sclerosis
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Relevant Topics

Flavia Nelson

Flavia Nelson Flavia Nelson Department of Neurology, University of Texas Health Science Center-Houston, Houston, TX, USA


Medical School University of Chihuahua School of Medicine Residency in Internal Medicine Texas Tech University Health Science Center Residency in Neurology University of Texas Medical School at Houston Multiple Sclerosis Clinical and Research Fellowship Multiple Sclerosis Research Group, University of Texas Medical School at Houston

Research Interest

Principal Investigator for the following protocols Detection of MS Related Cognitive Impairment: In Search of MRI Surrogate Markers Major aims of this project is to develop and apply a multimodal MRI approach to the evaluation of cognitive impairment in patients with multiple sclerosis. Low Dose fingolimod (0.25 mg) We are currently enrolling in a multicenter trial to compare the effectiveness and safety of low dose 0.25 mg fingolimod and 0.5 mg fingolimod with Copaxone 20mg subcutaneously in RRMS patients. The new oral agent fingolimod has already been approved for 0.5 mg dose, which blocks migration of T cells from the lymph node to the blood stream, and therefore the brain, significantly reducing number of attacks in RRMS patients. To be eligible for this study, patients should be in between the ages of 18–65, have at least 1 documented relapse during the previous year or 2 documented relapses during the previous 2 years.


Global Speakers in the subject

Global Experts in the subject